Hospital Universitari de Bellvitge Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2006
NCT00396721
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Daniel Podzamczer | Isabel Lopez Zamora | José María Piulats Rodríguez | Josep Maria Ramon Torrell, PhD | Josep m Cruzado | Josep M Cruzado | M. Carmen Cabellos Minguez | Miguel Santín | Núria Sabé Fernàndez | Sebastian Videla | Unidad de Trasplante Renal - Hospital Universitari de Bellvitge

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyslipidemias (Phase 4)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Kidney Diseases (Phase 2)

Meningitis (Phase 4)

Meningitis, Pneumococcal (Phase 4)

Neoplasm Metastasis (Phase 4)

Seizures (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 18